- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06285812
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children (OTO-MATIC)
OTO-MATIC: Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mixed method, multi-center, pragmatic, cluster-randomized effectiveness-implementation investigation focused on pediatric subjects presenting with ear complaints at the office setting.
For the prospective randomized component, eligible clinicians at a given site will be randomized to one of two groups: the OtoSight intervention group or the usual care control group. There will be three (3) periods of post-intervention assessment: 10 days (optional), 6 months, and 12 months.
Eligible subjects will be automatically enrolled (or invited to enroll) in the clinical trial and will receive information. Because this is a non-interference design, frontline care clinicians randomized to either arm will be asked to: (1) assess the presence or absence of fluid in the middle ear; (2) record a diagnosis; and (3) treat the patient as they would according to the information available to them.
A separate retrospective historical matched control arm will also be conducted to analyze potential Hawthorne effect at a subset of collaborating practices or healthcare systems. Randomization of clinicians (and not children) will decrease contamination in the usual practice group (i.e., so clinicians are not asked to flip between intervention and usual care practices).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Madeleine M. Martine, MA
- Phone Number: 1 6517283403
- Email: mad.martine0223@gmail.com
Study Contact Backup
- Name: Ryan Nolan, M.Eng., CCRP
- Phone Number: 1 664113277
- Email: rnolan@photoni.care
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Not yet recruiting
- Children's National Hospital
-
Contact:
- Bobbe Thomas
-
-
New York
-
Rochester, New York, United States, 14620
- Recruiting
- Trillim Health
-
Contact:
- Shealynn Hilliard
-
-
Oregon
-
Gresham, Oregon, United States, 97030
- Recruiting
- Cyn3rgy Research
-
Contact:
- Allie Calaman
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Recruiting
- Carolina ENT
-
Contact:
- Simone Ansley
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pediatric subjects between 6 months and 17 years of age
- Pediatric subjects presenting for an office visit with ear-related pain (otalgia)/otic complaints/earache indicative of potential Otitis Media with Effusion (OME) or Acute Otitis Media (AOM)
- Pediatric subjects where otoscopy would traditionally be indicated
- Pediatric subjects whose parents or legally authorized representative (LAR) have signed an informed consent
Exclusion Criteria:
- The parent or guardian who attends visits does not speak the same language as their physician
- Pediatric subjects enrolled in another clinical trial
- Pediatric subjects with:
- Signs of severe chronic illness (e.g., immunodeficiency, congenital heart disease, encephalopathy, pulmonary disease other than asthma, and disorder of the ear, nose and throat) or any clinically significant illness or condition that, in the opinion of the investigator, would prohibit the subject from participating in the trial
- Anatomical conditions that would affect their ability to undergo an otoscopy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Standard of Care #1
Prospective Randomized Control Trial (RCT)
|
|
OtoSight #1
Prospective Randomized Control Trial (RCT)
|
Subjects will be evaluated with the OtoSight Middle Ear Scope
|
OtoSight #2
Case and provider match
|
Subjects will be evaluated with the OtoSight Middle Ear Scope
|
Standard of Care #2
Retrospective case and provider matched controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change the clinician rate of antibiotic prescriptions
Time Frame: Baseline to 12 month Follow Up
|
Antibiotic stewardship
|
Baseline to 12 month Follow Up
|
Change the number of antibiotic rounds per patient
Time Frame: Baseline to 12 month Follow Up
|
Antibiotic stewardship
|
Baseline to 12 month Follow Up
|
Change costs associated with management of pediatric patients presenting with ear-related pain
Time Frame: Baseline to 21 month Follow Up
|
Change in overall costs
|
Baseline to 21 month Follow Up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in unnecessary antibiotic prescriptions
Time Frame: Baseline to 12 month Follow Up
|
Change in unnecessary antibiotic prescriptions based on reported diagnosis and treatment recommendations of providers
|
Baseline to 12 month Follow Up
|
Change in prescription adherence
Time Frame: Baseline to 12 month Follow Up
|
Change in prescription adherence
|
Baseline to 12 month Follow Up
|
Change in antibiotic prescription rate when fluid not present
Time Frame: Baseline to 12 month Follow Up
|
Change in antibiotic prescriptions rate when fluid is not present based on reported treatment recommendations of providers
|
Baseline to 12 month Follow Up
|
Improve patient outcomes
Time Frame: Baseline to 12 month Follow Up
|
Change in progression to recurrent AOM (rAOM) based on tracking provider diagnoses
|
Baseline to 12 month Follow Up
|
Change medical resource utilization
Time Frame: Baseline to 30 days Follow Up
|
Change in follow-up visit frequency, ENT (Ear, Nose, and Throat) referral frequency
|
Baseline to 30 days Follow Up
|
Change unnecessary medical intervention
Time Frame: Baseline to 12 month Follow Up
|
Change in amount of unnecessary medical intervention (e.g., tympanostomy tube surgeries) based on tracking provider treatment recommendations and diagnoses
|
Baseline to 12 month Follow Up
|
Impact clinician confidence
Time Frame: Baseline to 12 month Follow Up
|
Change in clinician confidence scores reported on Provider CRF
|
Baseline to 12 month Follow Up
|
Impact caregiver satisfaction
Time Frame: Baseline to 12 month Follow Up
|
Change in clinician satisfaction scores reported on Provider CRF
|
Baseline to 12 month Follow Up
|
Change in Health-related Quality of Life (HQoL)
Time Frame: Baseline to 12 month Follow Up
|
Change in HQoL scores reported on the OMO-22 and OM-6
|
Baseline to 12 month Follow Up
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 000003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Otitis Media Acute
-
AcclarentCompletedRecurrent Acute Otitis Media | Acute Otitis Media | Chronic Otitis MediaUnited States
-
David Chi, MDRecruitingRecurrent Acute Otitis Media | Chronic Otitis Media With Effusion | Otitis Media in ChildrenUnited States
-
Medical College of WisconsinNational Institutes of Health (NIH); National Institute on Deafness and Other... and other collaboratorsRecruitingOtitis Media | Otitis Media With Effusion | Otitis Media AcuteUnited States
-
Smith & Nephew, Inc.RecruitingOtitis Media | Otitis Media With Effusion | Acute Otitis MediaUnited States
-
AcclarentCompletedOtitis Media With Effusion | Acute Otitis MediaUnited States
-
Tusker MedicalCompletedAOM - Acute Otitis Media | OME - Otitis Media With EffusionUnited States, Canada
-
Rochester General HospitalActive, not recruitingDynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens (AOM)Acute Otitis MediaUnited States
-
University of OuluOulu University HospitalCompletedAcute Otitis MediaFinland
-
University of WashingtonStandard Homeopathic CompanyCompleted
-
PfizerCompletedAcute Otitis MediaCosta Rica
Clinical Trials on OtoSight Middle Ear Scope
-
PhotoniCare, Inc.National Institute on Deafness and Other Communication Disorders (NIDCD); Carle... and other collaboratorsCompleted
-
PhotoniCare, Inc.University of Pittsburgh; National Institute on Deafness and Other Communication...Completed
-
Baylor College of MedicineActive, not recruitingOtitis Media | Middle Ear Infection | Ear InfectionUnited States
-
Cuneyt M. AlperNational Institute on Deafness and Other Communication Disorders (NIDCD)Terminated
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedChronic Serous Otitis Media, Simple or UnspecifiedFrance
-
Association Clinique Thérapeutique Infantile du...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
MED-EL Elektromedizinische Geräte GesmbHCompleted
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
Yuinvent Innovations Ltd.UnknownOtitis Media With Effusion